17 Million for Future Cancer Diagnoses
After a successful market entry in the DACH Region (Germany, Austria and Switzerland) and the opening of a subsidiary office in Krakow, Poland, inveox continues to grow. With its largest investment so far of 17 million euros, the Munich startup will begin the series-level production of their AI-supported automation system in order to make cancer diagnoses faster and more reliable.
It all began with an idea: to help people by significantly improving the reliability of cancer diagnoses. To the founders, concepts like digitalization, automation and artificial intelligence also belong in the world of histopathology. These have the potential to enable faster and safer cancer diagnoses by enhancing the arrival and processing of tissue samples in a lab. Four business angels believed in this vision, and in 2017 they supported the founders with an investment of 1 million euros. In the summer of 2018 there was a growth investment of 5 million from the same investors. To Managing Partner Dominik Sievert, the most recent investment means more than financial support: “the investors believe in us because inveox has displayed unprecedented strong growth in just a short time. They believe in our product, our leadership and our vision, and more importantly they provide us with an invaluable asset beyond the investment: mentoring.”
“My founding partner Dominik Sievert and I are very grateful that our investors put such great trust in us and our vision. Together we are working towards the goal of using our innovation capacities to develop technologies that can be put to serve people. We want to help lab technicians who give their best every day at labs and we want to ensure the safety of patients as well as the speed and reliability of the entire diagnostic process. That’s why we will use this further investment for our forthcoming series production and expansion into new markets,” says Managing Partner Maria Sievert.
Currently, the IoT/SaaS integral system – consisting of a lab automation machine, an intelligent sample container, and AI-enhanced software – is being implemented with several customers in the D/A/CH region including well-known university clinics in Germany. The entry into further markets within and outside of Europe is planned for the later this year.
- cancer diagnostics
- artificial intelligence
- 1analytica 2020: New instruments for battery research
- 2Trends in analysis
- 3Finding the source of chemical reactions
- 4Gene scissors against incurable muscular disease
- 5Scientists learn more about the first hours of a lithium-ion battery's life
- 6First view of hydrogen at the metal-to-metal hydride interface
- 7Applied Photophysics board appoints Tim Flanagan as CEO
- 8Chemicals in the environment: A focus on mixtures
- 9Machine learning technique speeds up crystal structure determination
- 10The shape of water: What water molecules look like on the surface of materials